SEC Form 4 · accession 0001209191-16-133910
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roy D. Baynes
Director
Period of report
Jul 19, 2016
Accepted (ET)
Jul 26, 2016 · 1:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2016 | A | 4,000 | $0.00 | A | 4,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $17.50 | Jul 19, 2016 | A | 16,000 | A | — | Jul 18, 2026 | Common Stock | 16,000 | 16,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in twelve equal quarterly installments following the grant date.